2607:HKEXShanghai Pharmaceuticals Holding Co. Ltd. Class H Analysis

The stock’s price (0.545 MYR) sits above its 20‑day, 50‑day and 200‑day SMAs (0.535, 0.448 and 0.398 respectively), indicating a clear technical upward trend, while the RSI of 52 suggests only a marginal bullish bias. However, the MACD histogram is negative and the MACD signal is flagged as "bearish," suggesting a possible near‑term pull‑back. Volume is on a rising trajectory and the beta of 0.89 points to moderate market sensitivity, yet the 30‑day volatility soars above 110%, flagging substantial risk. From a valuation standpoint, the price‑to‑book ratio (0.357) and a low P/B suggest a modest valuation against assets, but the DCF‑derived fair value (≈0.13 MYR) and a price‑to‑sales multiple of 13.4 indicate the stock is overvalued relative to earnings and sales. The company’s financial health is weak: gross margin is 48%, but operating and profit margins are negative (‑1.72% and ‑0.57% respectively), EBITDA is –8.13 M, and ROE/ROA are both below zero. Despite a 71.5% revenue growth rate and a modest debt‑to‑equity of 0.075, the negative profitability and high drawdown (‑23.9%) compound the risk picture.